In SGC excluding ACC (CD73 expression on immune cells), this therapeutic strategy of targeting the adenosine pathway seems to be the most promising in light of high CD39 expression levels on both tumor and immune cells. The gene discussed is ENTPD1; the disease is neoplasm.